Soterix Medical, Inc.

Soterix Medical, Inc., doing business as Soterix Medical Technologies, is a for-profit manufacturer of transcranial electrical stimulation (tES) and neuromodulation medical devices and equipment based in Woodbridge, New Jersey, that operates primarily as a prime contractor to federal research and clinical agencies, with supplementary sub-recipient activity on NIH-funded grants. The vendor competes full-and-open across federal markets, holding no formal SBA certifications but winning recurring small-business set-asides on Small Business Innovation Research (SBIR) contracts and clinical purchase orders.

Soterix Medical's core capability is design, manufacture, and delivery of noninvasive brain stimulation systems — including transcranial direct current stimulation (tDCS) waveform generators, high-definition electrical stimulators, EEG recorders, and specialized research devices. Representative prime awards include a $1.1 million NASA SBIR Phase II contract (May 2022, ultimate completion September 2026) for advancing and validating the Galvanic Induced Disorientation Simulation Trainer (GIST) technology supporting aerospace crew performance research; a $1 million Department of Education Institute of Education Sciences SBIR Phase II award (May 2022–May 2024) for research and development services; a $1.1 million Defense Health Agency SBIR Direct-to-Phase-II contract (September 2022, completion July 2025) for the AeroRelief in-flight certified pain-relief device; and a series of smaller ($25,000–$107,850) purchase orders from the Department of Veterans Affairs Veterans Health Administration and National Institutes of Health for HD-tES systems, waveform generators, and EEG equipment. Soterix Medical also acts as a sub-recipient on NIH-funded grants, providing device manufacturing, current flow modeling, and training support under prime grants from New York University and Icahn School of Medicine at Mount Sinai focused on transcranial direct current stimulation interventions for cannabis use disorder and mental health conditions.

Customer concentration spans federal research and clinical agencies with significant dispersion. The top five funding agencies by either award count or potential value account for 46–87% of the portfolio depending on the ranking. By award count, the National Institute on Drug Abuse leads with six awards ($2 million combined potential value), followed by Veterans Integrated Service Network 10 (five awards, $81 thousand), NASA Shared Services Center (five awards, $1.1 million), and VISN 7 and the National Institute of Mental Health (four awards each). By potential value, the Defense Advanced Research Projects Agency tops the list with two awards ($2.2 million combined potential value), closely followed by NIDA (six awards, $2 million) and the Defense Health Agency (two awards, $1.3 million). The portfolio reflects a balanced mix of clinical/operational purchases from VA networks and research funding from NIH institutes, DoD research arms, NASA, and the Department of Education.

Activity has been episodic: eight awards in 2021, five in 2022, then a two-year dip to one award in 2023, before recovery to four awards each in 2025 and 2026. Combined potential value across all 52 awards is $9 million, though obligated dollars ($15.9 million) exceed the potential value by 77%, reflecting the vendor's history of multiple-phase SBIR completions and invoice activity above contract ceilings. Awards completing in the next twenty-four months total only $84 thousand in combined potential value, a minimal recompete cliff. Soterix Medical's top NAICS categories are Analytical Laboratory Instrument Manufacturing (18 awards) and Research and Development in the Physical, Engineering, and Life Sciences (10 awards); the top PSC codes are Laboratory Equipment and Supplies (16 awards) and Medical and Surgical Instruments, Equipment, and Supplies (nine awards).

Soterix Medical operates as a prime in 94% of awards and a sub-recipient in 6%. Service Contract Inventory reports minimal scope: $385 thousand in invoiced revenue across one fiscal year (FY2024) against 1.3 FTEs, with median government-paid rates of $147.70 per hour. SCI captures only service contracts above the $150,000 threshold and excludes goods and product sales, which dominate Soterix Medical's footprint; the $385 thousand SCI figure represents a thin slice of the vendor's federal activity and is not representative of total enterprise revenue.